CA2671778A1 - Immediate release dosage form of bosentan and process of manufacturing such - Google Patents
Immediate release dosage form of bosentan and process of manufacturing such Download PDFInfo
- Publication number
- CA2671778A1 CA2671778A1 CA2671778A CA2671778A CA2671778A1 CA 2671778 A1 CA2671778 A1 CA 2671778A1 CA 2671778 A CA2671778 A CA 2671778A CA 2671778 A CA2671778 A CA 2671778A CA 2671778 A1 CA2671778 A1 CA 2671778A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- active ingredient
- minutes
- immediate release
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 49
- 239000012729 immediate-release (IR) formulation Substances 0.000 title claims abstract description 32
- 230000008569 process Effects 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 229960003065 bosentan Drugs 0.000 title claims description 15
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 title description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 52
- 238000004090 dissolution Methods 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 38
- 239000008187 granular material Substances 0.000 claims description 30
- 239000011230 binding agent Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 229940036810 bosentan monohydrate Drugs 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 15
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 15
- 239000008109 sodium starch glycolate Substances 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 13
- 238000005550 wet granulation Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 229920003081 Povidone K 30 Polymers 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000007580 dry-mixing Methods 0.000 claims description 5
- 102000010180 Endothelin receptor Human genes 0.000 claims description 4
- 108050001739 Endothelin receptor Proteins 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical group O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 claims 4
- 150000004682 monohydrates Chemical group 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940118436 tracleer Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000009700 powder processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The present invention provides an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein the in vitro dissolution rate of the said dosage form provides at least 90% of the active ingredient dissolved within 30 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C; and a process for manufacturing the said dosage form.
Description
IMMEDIATE RELEASE DOSAGE FORM OF BOSENTAN
AND PROCESS OF MANUFACTURING SUCH
FIELD OF THE INVENTION
The present invention relates to an immediate release oral pharmaceutical dosage form containing a high dose poorly soluble active ingredient, more specifically the present invention is directed to dosage forms containing Bosentan_ BACKGROUND OF THE INVENTION
Bosentan is used for the treatment or prevention of endothelin-receptor mediated disorder, as pulmonary arterial hypertension (PAH).
Bosentan monohydrate being a poorly water soluble drug (1mg/100mi), leads to the great difficulty in the formulation of immediate release dosage form containing such. Poor water solubility and high dose content makes it difficult to develop a robust formulation and manufacturing process.
Poor dissolution behavior is observed for many water-insoluble drugs, which limits their bioavallability. Such low solubility can often result in low bioavailability, particularly given limited transit times through the gastrointestinal tract.
The Bosentan molecule has the following chemical formula:
0s0 'NH C1~CH3 HaC I õr CHI N I Hz0 OH
~
BOSENTAN (Tracleer ) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH, functional class III or IV), accordingly to World Health Organisation (WHO) and secondary to congenital heart disease and to human immunodeficiency virus (HIV).
The preparation of Bosentan is disclosed in the following patents EP 0 526 708, CA 2,071,193, US
5,292,740, CA 2,397,258 and US 5,883,254.
Accordingly to the World Standard Drug Database, the commercial available formulation of Tracleer has the following composition' Bosentan (the API) (125 or 62.5mg) and tablet contents: corn starch, glyceryl behenate, magnesium stearate, povidone, pregelatinized starch and sodium starch glycolate; and film coating; ethylcellulose, hydroxypropylmethylcellulose, iron oxide red, Iron oxide yellow, talc, titanium dioxide and triacetin.
The various techniques to make immediate release dosage form of drugs as described in prior art are as follows:
CA 2,607,098 disclosed a dispersible tablet, wherein Bosentan monohydrate form is used for pediatric formulation, which disintegrates completely in water at 15-22 C in no more than 5 minutes.
The dispersible tablets were obtained by using the method of direct compression.
WO 2004/012700 discloses a dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release'where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form, but bosentan is not exemplified).
The pharmaceutical industry employs various methods for compounding pharmaceutical agents in tablet formulations. Wet granulation methods are known in the art and have been described in detail by Dilip M.Parikh (Handbook of Pharmaceutical Granulation Technology, 2"d ed., 2005 ISBN00824726472). In particular, wet granulation is one of the most prevalent methods, which can be used where the flow properties of a compound such as an active pharmaceutical ingredient ('API") are poor which result in content uniformity issues when formulated as a, dry blend. Wet granulation is commonly used to improve the processing characteristics of a powder blend, including improved flowability, content uniformity and more uniform particle size.
CA 2,326,349 describes the process for manufacturing a pulverous preparation of a submicronized biologically active compounds (such as bosentan) using conventional powder processing techniques.
US 20060018934 discloses a novel modified release dosage form comprising of a high solubility active ingredient and optionally comprise another active ingredient as an immediate release form and process for preparing.
CA 2603316 relates to a process for the solid oral pharmaceutical formulation of a pharmaceutically active ingredient, levetiracetam, which is exemplified, comprising a wet granulation of levetiracetam and simultaneous fluid bed drying such that it is simultaneously dried, thus preventing it from becoming a paste.
US 20080026062 describes a pharmaceutical composition which comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical composition can be micronized or in the form of a film that can be rolled up. If micronized, the individual micron-sized particles can have a plurality of nano-sized particles present in the micron-sized particles.
Similarly, US 20080026040 describes a pharmaceutical composition which Is provided having a plurality of polymeric film layers heat sealed together as a multilayer structure and having an active agent dispersed within the multilayer structure. The multilayer structure is configured to release the active agent upon administration to a subject, either in a controlled release or immediate release manner.
WO 2009/004374 relates to an improved process for the preparation of Bosentan.
In particular it relates to a process for preparing bosentani substantially free from impurities and to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.
Bosentan monohydrate is currently being marketed as a tablet for the treatment of PAH, a deadly disease if untreated. The need to use active ingredients with different mechanisms of action, especially with immediate release dosage form, since the dose of Bosentan is very high it makes it very difficult to manufacture the product to obtain reproducible results.
Therefore, accordingly a need exists for a dosage form providing a highly insoluble drug in an immediate release dosage forms.
AND PROCESS OF MANUFACTURING SUCH
FIELD OF THE INVENTION
The present invention relates to an immediate release oral pharmaceutical dosage form containing a high dose poorly soluble active ingredient, more specifically the present invention is directed to dosage forms containing Bosentan_ BACKGROUND OF THE INVENTION
Bosentan is used for the treatment or prevention of endothelin-receptor mediated disorder, as pulmonary arterial hypertension (PAH).
Bosentan monohydrate being a poorly water soluble drug (1mg/100mi), leads to the great difficulty in the formulation of immediate release dosage form containing such. Poor water solubility and high dose content makes it difficult to develop a robust formulation and manufacturing process.
Poor dissolution behavior is observed for many water-insoluble drugs, which limits their bioavallability. Such low solubility can often result in low bioavailability, particularly given limited transit times through the gastrointestinal tract.
The Bosentan molecule has the following chemical formula:
0s0 'NH C1~CH3 HaC I õr CHI N I Hz0 OH
~
BOSENTAN (Tracleer ) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH, functional class III or IV), accordingly to World Health Organisation (WHO) and secondary to congenital heart disease and to human immunodeficiency virus (HIV).
The preparation of Bosentan is disclosed in the following patents EP 0 526 708, CA 2,071,193, US
5,292,740, CA 2,397,258 and US 5,883,254.
Accordingly to the World Standard Drug Database, the commercial available formulation of Tracleer has the following composition' Bosentan (the API) (125 or 62.5mg) and tablet contents: corn starch, glyceryl behenate, magnesium stearate, povidone, pregelatinized starch and sodium starch glycolate; and film coating; ethylcellulose, hydroxypropylmethylcellulose, iron oxide red, Iron oxide yellow, talc, titanium dioxide and triacetin.
The various techniques to make immediate release dosage form of drugs as described in prior art are as follows:
CA 2,607,098 disclosed a dispersible tablet, wherein Bosentan monohydrate form is used for pediatric formulation, which disintegrates completely in water at 15-22 C in no more than 5 minutes.
The dispersible tablets were obtained by using the method of direct compression.
WO 2004/012700 discloses a dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release'where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form, but bosentan is not exemplified).
The pharmaceutical industry employs various methods for compounding pharmaceutical agents in tablet formulations. Wet granulation methods are known in the art and have been described in detail by Dilip M.Parikh (Handbook of Pharmaceutical Granulation Technology, 2"d ed., 2005 ISBN00824726472). In particular, wet granulation is one of the most prevalent methods, which can be used where the flow properties of a compound such as an active pharmaceutical ingredient ('API") are poor which result in content uniformity issues when formulated as a, dry blend. Wet granulation is commonly used to improve the processing characteristics of a powder blend, including improved flowability, content uniformity and more uniform particle size.
CA 2,326,349 describes the process for manufacturing a pulverous preparation of a submicronized biologically active compounds (such as bosentan) using conventional powder processing techniques.
US 20060018934 discloses a novel modified release dosage form comprising of a high solubility active ingredient and optionally comprise another active ingredient as an immediate release form and process for preparing.
CA 2603316 relates to a process for the solid oral pharmaceutical formulation of a pharmaceutically active ingredient, levetiracetam, which is exemplified, comprising a wet granulation of levetiracetam and simultaneous fluid bed drying such that it is simultaneously dried, thus preventing it from becoming a paste.
US 20080026062 describes a pharmaceutical composition which comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical composition can be micronized or in the form of a film that can be rolled up. If micronized, the individual micron-sized particles can have a plurality of nano-sized particles present in the micron-sized particles.
Similarly, US 20080026040 describes a pharmaceutical composition which Is provided having a plurality of polymeric film layers heat sealed together as a multilayer structure and having an active agent dispersed within the multilayer structure. The multilayer structure is configured to release the active agent upon administration to a subject, either in a controlled release or immediate release manner.
WO 2009/004374 relates to an improved process for the preparation of Bosentan.
In particular it relates to a process for preparing bosentani substantially free from impurities and to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.
Bosentan monohydrate is currently being marketed as a tablet for the treatment of PAH, a deadly disease if untreated. The need to use active ingredients with different mechanisms of action, especially with immediate release dosage form, since the dose of Bosentan is very high it makes it very difficult to manufacture the product to obtain reproducible results.
Therefore, accordingly a need exists for a dosage form providing a highly insoluble drug in an immediate release dosage forms.
An object of the present invention is a formulation, which gives accurate dosing and is prepared by advantageous and simple process.
A further object of the present invention is to provide a wet granulation process for making such a novel granulate that may be used in solid oral dosage forms as immediate release tablets.
SUMMARY OF THE INVENTION
An object of the present invention provides for an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein the in vitro dissolution rate of the said dosage form provides at least 90% of the active ingredient dissolved within 30 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 370 C.
Preferably, the poorly soluble active ingredient is Bosentan or a pharmaceutically acceptable salt thereof.
More preferably, wherein said active ingredient is in monchydrate form, which is present in a high dose about of 125 mg.
Preferably, the process used to make the immediate release oral pharmaceutical dosage form is a wet granulation process which allows to get good granules and flow properties.
Another object of the present invention provides for an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 45 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1 % SDS at 370C.
USP Paddle Method is the Paddle Method described, e.g., in U.S Pharmacopoeia XXII (1990).
An object of the present invention provides an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 60 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1 % SDS at 37 C.
A further object of the present invention is to provide a wet granulation process for making such a novel granulate that may be used in solid oral dosage forms as immediate release tablets.
SUMMARY OF THE INVENTION
An object of the present invention provides for an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein the in vitro dissolution rate of the said dosage form provides at least 90% of the active ingredient dissolved within 30 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 370 C.
Preferably, the poorly soluble active ingredient is Bosentan or a pharmaceutically acceptable salt thereof.
More preferably, wherein said active ingredient is in monchydrate form, which is present in a high dose about of 125 mg.
Preferably, the process used to make the immediate release oral pharmaceutical dosage form is a wet granulation process which allows to get good granules and flow properties.
Another object of the present invention provides for an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 45 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1 % SDS at 370C.
USP Paddle Method is the Paddle Method described, e.g., in U.S Pharmacopoeia XXII (1990).
An object of the present invention provides an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 60 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1 % SDS at 37 C.
Yet another object of the present invention also provides a process for the preparation of an immediate release oral pharmaceutical dosage form containing a high dose of a poorly soluble active ingredient, wherein said process comprises the following steps;
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5);
(7)- screening the granules obtained from step (8)1-(8) - adding to the granules of step (7) pharmaceutically acceptable excipients;
(9) - mixing the mixture of step (8) using a suitable blender;
(10) - compressing the content of step (9).
Preferably, the poorly soluble active ingredient is Bosentan monohydrate and according to the process, wherein the content from step1 comprises: as active pharmaceutical ingredient -Bosentan monohydrate and as pharmaceutically acceptable excipients:
pregelatinized starch, Povidone-K30, Sodium starch glycolate and magnesium stearate.
Also, preferably the content of step (1) is passed through a 20 mesh manual screen and than dry mixed in small high shear for 3 minutes, wherein the binder solution is prepared by adding Povidone K30 to purified water and mixing for 30 minutes or until a clear solution is obtained, wherein the drying of the wet mass is carried out in a small fluid bed dryer for a period of about 45 minutes and wherein the granules obtained from step (7), are passed through 0.045 inches comill screen at low speed, wherein a pregelatinized starch and sodium starch glycolate are added to said granules and mixed for 2 minutes using a suitable blender, then a lubricant is added and mixed with mixture obtained from step (9), prior to compression, such as Magnesium stearate which is passed through a 40 mesh manual screen, added to the mixture obtained from step (9) and mixed for 3 minutes using a suitable blender, prior to compression.
An object of the present invention also provides a process for the preparation of an immediate release oral pharmaceutical dosage form containing high dose of a poorly soluble active ingredient.
wherein the in vitro dissolution rate of the said dosage form provides at least 90% of the active ingredient dissolved within 30 minutes, as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37 C, wherein said p cess comprising wet granulation step and fluid bed drying step as follows:
(1) - screening Bosentan monohydrate and pr gelatinized starch, povidone and sodium starch glycolate through a 20 mesh manual screen;
(2) - dry mixing the content of step (1) in a small high shear for 3 minutes;
(3) - preparing a binder solution by adding Povione K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear (solution is obtained;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5) in small fluid bed for a period of about 45 minutes;
(7) - screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pregelatinized starch and sodium starch glycolate;
(9) - mixing the mixture obtained from step (8) for 2 minutes using a suitable blender;
(10) - screening magnesium stearate through a 40 mesh manual screen;
Preferably, the poorly soluble active ingredient is Bosentan monohydrate and according to the process, wherein the content from step1 comprises: as active pharmaceutical ingredient -Bosentan monohydrate and as pharmaceutically acceptable excipients:
pregelatinized starch, Povidone-K30, Sodium starch glycolate and magnesium stearate.
Also, preferably the content of step (1) is passed through a 20 mesh manual screen and than dry mixed in small high shear for 3 minutes, wherein the binder solution is prepared by adding Povidone K30 to purified water and mixing for 30 minutes or until a clear solution is obtained, wherein the drying of the wet mass is carried out in a small fluid bed dryer for a period of about 45 minutes and wherein the granules obtained from step (7), are passed through 0.045 inches comill screen at low speed, wherein a pregelatinized starch and sodium starch glycolate are added to said granules and mixed for 2 minutes using a suitable blender, then a lubricant is added and mixed with mixture obtained from step (9), prior to compression, such as Magnesium stearate which is passed through a 40 mesh manual screen, added to the mixture obtained from step (9) and mixed for 3 minutes using a suitable blender, prior to compression.
An object of the present invention also provides a process for the preparation of an immediate release oral pharmaceutical dosage form containing high dose of a poorly soluble active ingredient.
wherein the in vitro dissolution rate of the said dosage form provides at least 90% of the active ingredient dissolved within 30 minutes, as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37 C, wherein said p cess comprising wet granulation step and fluid bed drying step as follows:
(1) - screening Bosentan monohydrate and pr gelatinized starch, povidone and sodium starch glycolate through a 20 mesh manual screen;
(2) - dry mixing the content of step (1) in a small high shear for 3 minutes;
(3) - preparing a binder solution by adding Povione K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear (solution is obtained;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5) in small fluid bed for a period of about 45 minutes;
(7) - screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pregelatinized starch and sodium starch glycolate;
(9) - mixing the mixture obtained from step (8) for 2 minutes using a suitable blender;
(10) - screening magnesium stearate through a 40 mesh manual screen;
(11) - mixing the content obtained from step (9) with the content from step (10) for 3 min using a suitable blender;
(12) - compressing the content obtained from step (11).
The present invention is further related to a prrcess for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form, comprising a wet granulation step and a fluid bed drying step.
The present invention is further related to use of said di sage form for the treatment or prevention of endothelin-receptor mediated disorder, wherein the disorder is pulmonary arterial hypertension.
DETAILED DESCRIPTION OF THE INVENTION
The resent invention relates to an Immediate r p s release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, using in the pro cess of manufacturing the wet granulation step and a fluid bed drying step in order to get good granules with excellent flow properties and desired dissolution profiles.
The term "immediate release" as used herein in relatipn to composition according to the invention or used in any other context means release which is (not modified release and releases more than 90% of the active ingredient within 30 minutes. The teen "immediate release dosage form" as used herein can be described as dosage form which allows the drug to dissolve in the gastrointestinal contents, with no intention of delaying or prolonging the dissolution or absorption of the drug (as per US FDA guideline for'SUPAC-MR : Modified Release Solid Oral Dosage Forms').
The term "dosage form" is intended to denote any form of the formulation that contains an amount sufficient to achieve a therapeutic effect with a single administration.
The term "active ingredient" refers to an Active Pharmaceutical Ingredients (APi) which are active chemicals used in the manufacturing of drugs. The active agent can be a therapeutic, a prophylactic, or a diagnostic agent. These terms of art are well-known to the person skilled in the pharmaceutical and medicinal arts.
The term "high dose" as used refers to the % with respect to total dosage form of weight.
In a preferred embodiment of the invention, the present invention provides a dosage form wherein the said active ingredient is Bosentan monohydrate or a pharmaceutically acceptable salt thereof.
In addition to the active ingredient, the pharmaceutical composition of the present invention contains pharmaceutically acceptable excipients added to the composition for a variety of purposes. One or more pharmaceutically acceptable excipients may be present in the composition of the present invention, such as for example. diluents, binders, lubricants, disintegrants, glidants, and acidifying agents. As understood by a person skilled in the art, these excipients are conventional excipients which are well known in the pharmaceutical art.
Preferably, according to the present invention suitable diluents include for example pharmaceutically acceptable inert fillers such as microcrystalline cellulose, lactose, pregelatinized starch, dibasic calcium phosphate, saccharides, and/or mixtures of the foregoing.
Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient referred to as binders and other excipients together before the compression.
Preferably, according to the present invention suitable binders include for example starch, povidone, hydroxypropylmethylcellulose, pregelatinized starch, hydroxypropylcellulose and/or mixtures of the foregoing.
Preferably, according to the present invention for suitable lubricants are selected from the group consisting. of. Mg-, Al- or Ca-stearate, steanc acid, sodium stearyl fumarate, talc, sodium benzoate, glyceryl mono fatty acid, glyceryl monostearate and mixtures thereof.
The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition.
Preferably, according to the present invention suitable disintegrants include for example croscarmellose sodium, sodium starch glycolate, maize starch, CIVIC-Ca, CMC-Na, microcrystalline cellulose, cross-linked PVP, alginic acid, sodium alginate, pregelatinized starch and guar gum.
A composition for tabletting or capsule filling may be prepared by wet granulation step. In wet granulation, the active ingredient and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water that causes the powders to clump into granules. The granules are screened and/or milled, dried and then screened and/or milled to the desired particle size. The granules may then be compressed into tablets, or other excipients may be added prior to tabletting, such as a glidant and/or a lubricant.
In a preferred aspect of the invention, an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient comprises as active ingredient Bosentan monohydrate or a pharmaceutically acceptable salt thereof and as pharmaceutically acceptable excipients:
pregelatinized starch, povidone-K30, sodium starch glycolate and magnesium stearate.
Oral dosage forms which may be employed with the present invention include granules, spheroids or pellets in a capsule or in any other suitable solid form. Preferably, however the oral dosage form is a tablet.
In a preferred aspect of the invention, oral dosage form preferably contains a dose about of 125 mg of Bosentan monohydrate. Alternatively, the dosage form may contain molar equivalent amounts of other pharmaceutically acceptable bosentan salts.
The granules can be manufactured in accordance with usual techniques in which the active ingredient and other pharmaceutically acceptable excipients are mixed and granulated by adding solution of binder in a low or high shear mixer or by fluidized bed granulation. The granules are then dried, preferably in a fluidized bed dryer. The dried granules are sieved and mixed with lubricants and disintegrants. Alternatively, the manufacture of granules can be made by direct mixing of the directly compressible excipients or by roller compaction.
Since Bosentan monohydrate is poorly soluble in water (1 mg/100ml) and in aqueous solutions at low pH, and especially in high dose, it was an achievement to obtain an immediate release dosage form, using wet granulation process to get good granules and flow properties.
Povidone K-30 plays a very important role as binder used in solution in order to get good granules when used in the range of (2-10) % w/w in the composition.
According to an object of the present invention, the process for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form comprises the following steps:
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5);
(7)- screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pharmaceutically acceptable excipients;
(9) - mixing the mixture of step (8) using a suitable blender;
(10) - compressing the content of step (9).
The following example illustrates the preferred embodiment and various aspects of the present invention.
Example I
Immediate Release Dosage Form of Bosentan According to a Preferred Embodiment of the Present Invention The required quantities of bosentan monohydrate, pregelatinized starch, povidone and sodium starch glycolate are passed through a 20 mesh manual screen and then dry mixed the content in a small high shear for 3 minutes;
The binder solution is prepared by adding Povidone K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear solution is obtained.
Then adding the binder solution to the dry blend mixture performing a granulation. The wet mass of obtained granules are then dried in small fluid bed for a period of about 45 minutes and then passed through 0.045. inches comill screen at low speed.
The required quantity of pregelatinized starch and sodium starch glycolate are added to obtain granules and mixed for 2 minutes using a suitable blender.
The granulate is then lubricated by mixing the required quantity of magnesium stearate which is screening through a 40 mesh manual screen; then added to the obtained mixture mixing for 3 min using a suitable blender prior to compression.
The tablets are compressed on a suitable tabletting machine.
The formulation of Example 1 is set out in Table I below.
Table I
Formulation according to the present invention Name of Ingredients No. Intra-granular components % wlw mgltablet' 1. Bosentan monohydrate 73.53 125.0 2. Pregelatinized starch 9.97 16.949 3. Povidone-K30 3.0 5.1 4. Povidone-K30 3.0 5.1 5. Sodium starch glycolate 5.0 8.5 Extra-granular components 6. Pregelatinized starch 5.0 8.5 7. Magnesium stearate 0.5 0-85 The tablets obtained from Example 1 were subsequently tested for in vitro dissolution rate, measured by Apparatus If (USP Paddle Method), using the following parameters:
Speed: 50 rpm Media: purified with 1 % SDS
Dissolution medium (buffer) - 900ml Temperature: 37 C.
The dissoluti n results are set out in Table 2 below.
T bole 2 Dissolution Rate of Bosentan Monohydrate Formulation of Example 1 Time (min) Reference product Tablets from (% dissolved) Example I
(% dissolved)
The present invention is further related to a prrcess for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form, comprising a wet granulation step and a fluid bed drying step.
The present invention is further related to use of said di sage form for the treatment or prevention of endothelin-receptor mediated disorder, wherein the disorder is pulmonary arterial hypertension.
DETAILED DESCRIPTION OF THE INVENTION
The resent invention relates to an Immediate r p s release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, using in the pro cess of manufacturing the wet granulation step and a fluid bed drying step in order to get good granules with excellent flow properties and desired dissolution profiles.
The term "immediate release" as used herein in relatipn to composition according to the invention or used in any other context means release which is (not modified release and releases more than 90% of the active ingredient within 30 minutes. The teen "immediate release dosage form" as used herein can be described as dosage form which allows the drug to dissolve in the gastrointestinal contents, with no intention of delaying or prolonging the dissolution or absorption of the drug (as per US FDA guideline for'SUPAC-MR : Modified Release Solid Oral Dosage Forms').
The term "dosage form" is intended to denote any form of the formulation that contains an amount sufficient to achieve a therapeutic effect with a single administration.
The term "active ingredient" refers to an Active Pharmaceutical Ingredients (APi) which are active chemicals used in the manufacturing of drugs. The active agent can be a therapeutic, a prophylactic, or a diagnostic agent. These terms of art are well-known to the person skilled in the pharmaceutical and medicinal arts.
The term "high dose" as used refers to the % with respect to total dosage form of weight.
In a preferred embodiment of the invention, the present invention provides a dosage form wherein the said active ingredient is Bosentan monohydrate or a pharmaceutically acceptable salt thereof.
In addition to the active ingredient, the pharmaceutical composition of the present invention contains pharmaceutically acceptable excipients added to the composition for a variety of purposes. One or more pharmaceutically acceptable excipients may be present in the composition of the present invention, such as for example. diluents, binders, lubricants, disintegrants, glidants, and acidifying agents. As understood by a person skilled in the art, these excipients are conventional excipients which are well known in the pharmaceutical art.
Preferably, according to the present invention suitable diluents include for example pharmaceutically acceptable inert fillers such as microcrystalline cellulose, lactose, pregelatinized starch, dibasic calcium phosphate, saccharides, and/or mixtures of the foregoing.
Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient referred to as binders and other excipients together before the compression.
Preferably, according to the present invention suitable binders include for example starch, povidone, hydroxypropylmethylcellulose, pregelatinized starch, hydroxypropylcellulose and/or mixtures of the foregoing.
Preferably, according to the present invention for suitable lubricants are selected from the group consisting. of. Mg-, Al- or Ca-stearate, steanc acid, sodium stearyl fumarate, talc, sodium benzoate, glyceryl mono fatty acid, glyceryl monostearate and mixtures thereof.
The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition.
Preferably, according to the present invention suitable disintegrants include for example croscarmellose sodium, sodium starch glycolate, maize starch, CIVIC-Ca, CMC-Na, microcrystalline cellulose, cross-linked PVP, alginic acid, sodium alginate, pregelatinized starch and guar gum.
A composition for tabletting or capsule filling may be prepared by wet granulation step. In wet granulation, the active ingredient and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water that causes the powders to clump into granules. The granules are screened and/or milled, dried and then screened and/or milled to the desired particle size. The granules may then be compressed into tablets, or other excipients may be added prior to tabletting, such as a glidant and/or a lubricant.
In a preferred aspect of the invention, an immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient comprises as active ingredient Bosentan monohydrate or a pharmaceutically acceptable salt thereof and as pharmaceutically acceptable excipients:
pregelatinized starch, povidone-K30, sodium starch glycolate and magnesium stearate.
Oral dosage forms which may be employed with the present invention include granules, spheroids or pellets in a capsule or in any other suitable solid form. Preferably, however the oral dosage form is a tablet.
In a preferred aspect of the invention, oral dosage form preferably contains a dose about of 125 mg of Bosentan monohydrate. Alternatively, the dosage form may contain molar equivalent amounts of other pharmaceutically acceptable bosentan salts.
The granules can be manufactured in accordance with usual techniques in which the active ingredient and other pharmaceutically acceptable excipients are mixed and granulated by adding solution of binder in a low or high shear mixer or by fluidized bed granulation. The granules are then dried, preferably in a fluidized bed dryer. The dried granules are sieved and mixed with lubricants and disintegrants. Alternatively, the manufacture of granules can be made by direct mixing of the directly compressible excipients or by roller compaction.
Since Bosentan monohydrate is poorly soluble in water (1 mg/100ml) and in aqueous solutions at low pH, and especially in high dose, it was an achievement to obtain an immediate release dosage form, using wet granulation process to get good granules and flow properties.
Povidone K-30 plays a very important role as binder used in solution in order to get good granules when used in the range of (2-10) % w/w in the composition.
According to an object of the present invention, the process for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form comprises the following steps:
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5);
(7)- screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pharmaceutically acceptable excipients;
(9) - mixing the mixture of step (8) using a suitable blender;
(10) - compressing the content of step (9).
The following example illustrates the preferred embodiment and various aspects of the present invention.
Example I
Immediate Release Dosage Form of Bosentan According to a Preferred Embodiment of the Present Invention The required quantities of bosentan monohydrate, pregelatinized starch, povidone and sodium starch glycolate are passed through a 20 mesh manual screen and then dry mixed the content in a small high shear for 3 minutes;
The binder solution is prepared by adding Povidone K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear solution is obtained.
Then adding the binder solution to the dry blend mixture performing a granulation. The wet mass of obtained granules are then dried in small fluid bed for a period of about 45 minutes and then passed through 0.045. inches comill screen at low speed.
The required quantity of pregelatinized starch and sodium starch glycolate are added to obtain granules and mixed for 2 minutes using a suitable blender.
The granulate is then lubricated by mixing the required quantity of magnesium stearate which is screening through a 40 mesh manual screen; then added to the obtained mixture mixing for 3 min using a suitable blender prior to compression.
The tablets are compressed on a suitable tabletting machine.
The formulation of Example 1 is set out in Table I below.
Table I
Formulation according to the present invention Name of Ingredients No. Intra-granular components % wlw mgltablet' 1. Bosentan monohydrate 73.53 125.0 2. Pregelatinized starch 9.97 16.949 3. Povidone-K30 3.0 5.1 4. Povidone-K30 3.0 5.1 5. Sodium starch glycolate 5.0 8.5 Extra-granular components 6. Pregelatinized starch 5.0 8.5 7. Magnesium stearate 0.5 0-85 The tablets obtained from Example 1 were subsequently tested for in vitro dissolution rate, measured by Apparatus If (USP Paddle Method), using the following parameters:
Speed: 50 rpm Media: purified with 1 % SDS
Dissolution medium (buffer) - 900ml Temperature: 37 C.
The dissoluti n results are set out in Table 2 below.
T bole 2 Dissolution Rate of Bosentan Monohydrate Formulation of Example 1 Time (min) Reference product Tablets from (% dissolved) Example I
(% dissolved)
Claims (11)
1. An immediate release oral pharmaceutical dosage form of a high dose of a poorly soluble active ingredient, wherein the in vitro dissolution rate of the said dosage form provides at least 95%
of the active ingredient dissolved within 30 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
of the active ingredient dissolved within 30 minutes as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
2. A dosage form according to claim 1, wherein the poorly soluble active ingredient is Bosentan or pharmaceutically acceptable salts.
3. A dosage form according to claim 2, wherein said active ingredient is in monohydrate form.
4. A dosage form according to claim 2 or 3, wherein said active ingredient is in the form of its sodium salt.
5. A dosage form according to any one of claims 1 to 4, wherein said active ingredient is present in a dose about of 125 mg.
6. A dosage form according to any one of claims 1 to 5, used in the treatment of pulmonary arterial hypertension (PAH).
7. A dosage form according to claims 1- 6, wherein the pharmaceutically acceptable excipients comprise: pregelatinized starch, povidone-K30, sodium starch glycolate and magnesium stearate.
8. An immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 45 minutes as measured by USP
Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
9. An immediate release oral pharmaceutical dosage form of a high dose poorly soluble active ingredient, wherein said active ingredient is fully dissolved within 60 minutes as measured by USP
Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C.
10. A process for the preparation of an immediate release oral pharmaceutical dosage form containing a high dose of a poorly soluble active ingredient, wherein said process comprises the following steps:
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5);
(7)- screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pharmaceutically acceptable excipients;
(9) - mixing the mixture of step (8) using a suitable blender;
(10) - compressing the content of step (9).
(1) - screening the active ingredient and pharmaceutical excipients;
(2) - dry mixing the content of step (1);
(3) - preparing a binder solution;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5);
(7)- screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pharmaceutically acceptable excipients;
(9) - mixing the mixture of step (8) using a suitable blender;
(10) - compressing the content of step (9).
11. A process for the preparation of an immediate release oral pharmaceutical dosage form containing a high dose of a poorly soluble active ingredient, wherein the in vitro dissolution rate of the said dosage form provides at least 95% of the active ingredient dissolved within 30 minutes, as measured by USP Paddle Method at 50 rpm at 900 ml of dissolution buffer with 1% SDS at 37°C, wherein said process comprises the following steps:
(1) - screening Bosentan monohydrate and pregelatinized starch, povidone and sodium starch glycolate through a 20 mesh manual screen;
(2) - dry mixing the content of step (1) in a small high shear for 3 minutes;
(3) - preparing a binder solution by adding Povidone K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear solution is obtained;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5) in small fluid bed for a period of about 45 minutes;
(7) - screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pregelatinized starch and sodium starch glycolate;
(9) - mixing the mixture obtained from step (8) for 2 minutes using a suitable blender;
(10) - screening magnesium stearate through a 40 mesh manual screen;
(11) - mixing the content obtained from step (9) with the content from step (10) for 3 min using a suitable blender and (12) - compressing the content obtained from step (11).
The process according to claim 10, wherein said poorly soluble active ingredient is Bosentan monohydrate.
13. The process according to claim 10, wherein the content from step1 comprises: as active ingredient - Bosentan monohydrate and as pharmaceutically acceptable excipients: pregelatinized starch, Povidone-K30 and sodium starch glycolate.
14. The process according to claim 10, wherein said content of step (1) is passed through a 20 mesh manual screen and then dry mixed in small high shear for 3 minutes.
15. The process according to claim 10, wherein the binder solution is prepared by adding Povidone to a sufficient quantity of purified water and mixing.
16. The process according to claim 10, wherein said binder solution is prepared by adding Povidone K30 to purified water and mixing for 30 minutes or until a clear solution is obtained.
17. The process according to claim 10, wherein the drying of the wet mass is carried out in a small fluid bed dryer for a period of about 45 minutes.
18. The process according to claim 10, wherein the granules obtained from step (7), are passed through 0.045 inches comill screen at low speed.
19. The process according to claim 10, wherein a pregelatinized starch and sodium starch glycolate are added to said granules and mixed for 2 minutes using a suitable blender.
20. The process according to claim 10, wherein a lubricant is added and mixed with mixture obtained from step (9), prior to compression.
21. The process according to claim 10, wherein magnesium stearate is passed through a 40 mesh manual screen, added to the mixture obtained from step (9) and mixed for 3 minutes using a suitable blender, prior to the compression step.
22. The process for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form, said process comprises a wet granulation step and a fluid bed drying step.
~. Use of a dosage form according to any one of claims 1-9 for the treatment or prevention of endothelin-receptor mediated disorder.
24. A use according to claim 23, wherein the disorder is pulmonary arterial hypertension.
(1) - screening Bosentan monohydrate and pregelatinized starch, povidone and sodium starch glycolate through a 20 mesh manual screen;
(2) - dry mixing the content of step (1) in a small high shear for 3 minutes;
(3) - preparing a binder solution by adding Povidone K30 to a sufficient quantity of purified water and mixing for 30 minutes or until a clear solution is obtained;
(4) - adding the binder solution of step (3) to the dry blend of step (2);
(5) - performing a granulation;
(6) - drying the wet mass obtained from step (5) in small fluid bed for a period of about 45 minutes;
(7) - screening the granules obtained from step (6);
(8) - adding to the granules of step (7) pregelatinized starch and sodium starch glycolate;
(9) - mixing the mixture obtained from step (8) for 2 minutes using a suitable blender;
(10) - screening magnesium stearate through a 40 mesh manual screen;
(11) - mixing the content obtained from step (9) with the content from step (10) for 3 min using a suitable blender and (12) - compressing the content obtained from step (11).
The process according to claim 10, wherein said poorly soluble active ingredient is Bosentan monohydrate.
13. The process according to claim 10, wherein the content from step1 comprises: as active ingredient - Bosentan monohydrate and as pharmaceutically acceptable excipients: pregelatinized starch, Povidone-K30 and sodium starch glycolate.
14. The process according to claim 10, wherein said content of step (1) is passed through a 20 mesh manual screen and then dry mixed in small high shear for 3 minutes.
15. The process according to claim 10, wherein the binder solution is prepared by adding Povidone to a sufficient quantity of purified water and mixing.
16. The process according to claim 10, wherein said binder solution is prepared by adding Povidone K30 to purified water and mixing for 30 minutes or until a clear solution is obtained.
17. The process according to claim 10, wherein the drying of the wet mass is carried out in a small fluid bed dryer for a period of about 45 minutes.
18. The process according to claim 10, wherein the granules obtained from step (7), are passed through 0.045 inches comill screen at low speed.
19. The process according to claim 10, wherein a pregelatinized starch and sodium starch glycolate are added to said granules and mixed for 2 minutes using a suitable blender.
20. The process according to claim 10, wherein a lubricant is added and mixed with mixture obtained from step (9), prior to compression.
21. The process according to claim 10, wherein magnesium stearate is passed through a 40 mesh manual screen, added to the mixture obtained from step (9) and mixed for 3 minutes using a suitable blender, prior to the compression step.
22. The process for the manufacturing of an oral pharmaceutical dosage form of a high dose of Bosentan monohydrate in an immediate release form, said process comprises a wet granulation step and a fluid bed drying step.
~. Use of a dosage form according to any one of claims 1-9 for the treatment or prevention of endothelin-receptor mediated disorder.
24. A use according to claim 23, wherein the disorder is pulmonary arterial hypertension.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2671778A CA2671778A1 (en) | 2009-07-10 | 2009-07-10 | Immediate release dosage form of bosentan and process of manufacturing such |
CA2709624A CA2709624A1 (en) | 2009-07-10 | 2010-07-09 | Immediate release dosage form of bosentan and process of manufacturing such |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2671778A CA2671778A1 (en) | 2009-07-10 | 2009-07-10 | Immediate release dosage form of bosentan and process of manufacturing such |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2671778A1 true CA2671778A1 (en) | 2011-01-10 |
Family
ID=43448712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2671778A Abandoned CA2671778A1 (en) | 2009-07-10 | 2009-07-10 | Immediate release dosage form of bosentan and process of manufacturing such |
CA2709624A Abandoned CA2709624A1 (en) | 2009-07-10 | 2010-07-09 | Immediate release dosage form of bosentan and process of manufacturing such |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2709624A Abandoned CA2709624A1 (en) | 2009-07-10 | 2010-07-09 | Immediate release dosage form of bosentan and process of manufacturing such |
Country Status (1)
Country | Link |
---|---|
CA (2) | CA2671778A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768068B (en) * | 2012-10-18 | 2016-09-07 | 北京万生药业有限责任公司 | A kind of Bosentan pharmaceutical composition |
-
2009
- 2009-07-10 CA CA2671778A patent/CA2671778A1/en not_active Abandoned
-
2010
- 2010-07-09 CA CA2709624A patent/CA2709624A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2709624A1 (en) | 2011-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6041919B2 (en) | Salt of 8-[{1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy} -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one Tablet formulations containing and tablets made therefrom | |
KR101552033B1 (en) | Pharmaceutical composition | |
KR100728846B1 (en) | High drug load tablet | |
AU2005271194A1 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | |
JPH08333253A (en) | Irbesartan containing pharmaceutical composition | |
AU2014257719B2 (en) | Pharmaceutical composition containing crystalline macitentan | |
CA2706292A1 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
JP2009524658A (en) | Levetiracetam preparation and method for producing the same | |
AU2014295100B2 (en) | Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. | |
WO2020175897A1 (en) | Controlled release formulation containing mirabegron or pharmaceutically acceptable salt thereof | |
WO2011064797A2 (en) | Controlled release pharmaceutical compositions of galantamine | |
CA2671778A1 (en) | Immediate release dosage form of bosentan and process of manufacturing such | |
US11260055B2 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
JP6854384B2 (en) | Pharmaceutical composition | |
JP6321131B2 (en) | Dissolution improvement method of amlodipine-containing combination tablets | |
CN105407875A (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
KR20150096787A (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
EP4279075A1 (en) | A pharmaceutical composition comprising elagolix | |
JP2017132724A (en) | Orally disintegrating tablet formulation comprising amlodipine-containing coated granulated material | |
WO2023126973A1 (en) | Stable pharmaceutical composition of elagolix | |
WO2024030098A1 (en) | A tablet of tolvaptan and at least one binder processed with spray granulation | |
WO2019030773A1 (en) | Low-dose diclofenac compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20120710 |